To assess the clinical effect of radium 223 (Ra223) in patients with progressive symptomatic bone metastases on a background of metastatic castrate resistant prostate cancer (mCRPC)

Autor: Charlotte Fisher, James D. Wylie, Catherine Coyle, Ananya Choudhury, Ruth Conroy, John P Logue, Tony Elliot, Christina J. Hague, Anna Tran

Publikováno v: Journal of Clinical Oncology. 34:347-347

347 Background: Ra223 is the first radiopharmaceutical shown in the ALSYMPCA trial to improve survival and achieve a tolerable safety profile in patients with symptomatic bone metastases. It remains unclear as to where Ra223 is best placed in the tre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::668af514df473042d01d583efa560d16
https://doi.org/10.1200/jco.2016.34.2_suppl.347

Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapy

Autor: Neil G Burnet, Thomas Mee, Simona Gaito, Norman F Kirkby, Adam H Aitkenhead, Carmel N Anandadas, Marianne C Aznar, Lisa H Barraclough, Gerben Borst, Frances C Charlwood, Matthew Clarke, Rovel J Colaco, Adrian M Crellin, Noemie N Defourney, Christina J Hague, Margaret Harris, Nicholas T Henthorn, Kirsten I Hopkins, E Hwang, Sam P Ingram, Karen J Kirkby, Lip W Lee, David Lines, Zoe Lingard, Matthew Lowe, Ranald I Mackay, Catherine A McBain, Michael J Merchant, David J Noble, Shermaine Pan, James M Price, Ganesh Radhakrishna, David Reboredo-Gil, Ahmed Salem, Srijith Sashidharan, Peter Sitch, Ed Smith, Edward AK Smith, Michael J Taylor, David J Thomson, Nicola J Thorp, Tracy SA Underwood, John W Warmenhoven, James P Wylie, Gillian Whitfield

Publikováno v: Burnet, N G, Mee, T, Gaito, S, Kirkby, N F, Aitkenhead, A H, Anandadas, C N, Aznar, M C, Barraclough, L H, Borst, G, Charlwood, F C, Clarke, M, Colaco, R J, Crellin, A M, Defourney, N N, Hague, C J, Harris, M, Henthorn, N T, Hopkins, K I, Hwang, E, Ingram, S P, Kirkby, K J, Lee, L W, Lines, D, Lingard, Z, Lowe, M, Mackay, R I, McBain, C A, Merchant, M J, Noble, D J, Pan, S, Price, J M, Radhakrishna, G, Reboredo-Gil, D, Salem, A, Sashidharan, S, Sitch, P, Smith, E, Smith, E A, Taylor, M J, Thomson, D J, Thorp, N J, Underwood, T S, Warmenhoven, J W, Wylie, J P & Whitfield, G 2022, ' Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapy ', The British journal of radiology, vol. 95, no. 1133, A5, pp. 20211175 . https://doi.org/10.1259/bjr.20211175

Objectives: High-energy Proton Beam Therapy (PBT) commenced in England in 2018 and NHS England commissions PBT for 1.5% of patients receiving radical radiotherapy. We sought expert opinion on the level of provision. Methods: Invitations were sent to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e07dd145358515d081f5c83c99768105